A Randomized Study of Lenvatinib 18 mg Vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. Brose MS, Panaseykin Y, Konda B, de La Fouchardiere C, et al. J Clin Endocrinol Metab 2021 Oct 19. pii: 6401965. doi: 10.1210.

Read + Share

Amedeo Smart

Independent Medical Education

Brose MS, Panaseykin Y, Konda B, de La Fouchardiere C, et al. A Randomized Study of Lenvatinib 18 mg Vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab 2021 Oct 19. pii: 6401965. doi: 10.1210.
PMID: 34664662